Biotech Firm Gameto Secures $44M Series C Funding to Advance Women's Health Innovation

• Gameto, a biotech firm based in Austin that focuses on women's health, has raised $44 million in Series C financing, total venture capital of $127 million
• Lead program of the Company, Fertilo, is currently being used clinically in Peru, Mexico, and Australia
• Fertilo is an induced pluripotent stem cell-based therapy that matures egg cells outside the body before IVF

Gameto, the clinical-stage biotechnology firm working on stem cell-derived therapies for reproductive health, reported the close of a $44 million Series C financing round led by Overwater Ventures and including participation from Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, Portfolia, and other investors.

This new increase puts Gameto's overall funding at a sector-leading $127 million, further testament to the promise of its platform and the accelerating progress toward late-stage clinical trials. The financing will be used to complete the current Phase 3 trial for its flagship program, Fertilo, and enable global regulatory submissions.

Fertilo has already been approved for commercialization in several other countries other than the U.S. and is being applied in clinics in Peru, Mexico, and Australia, with further approvals in Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay. As of now, the therapy has yielded five live births and more than 20 documented pregnancies.

"This is a critical time for Gameto and our mission to improve women's and family health," stated Dr. Dina Radenkovic Turner, CEO and co-founder of Gameto. "With this round, we are able to finish our Phase 3 trial of Fertilo and assess its safety and efficacy at top U.S. study sites."

The Fertilo In Vitro Research Study and Trial (FIRST) is the initial randomized, controlled, double-blind trial in the United States to assess egg maturation ex vivo, and the first to study stem cell technology in IVF. This support also allows us to diversify our pipeline of next-generation therapeutics in an under researched and underserved field.

Fertilo is a major innovation in in vitro fertilization, employing genetically engineered ovarian support cells (OSCs) from induced pluripotent stem cells (iPSCs) to guide eggs to maturity outside the human body. It reduces the conventional ovarian stimulation cycle of two weeks of daily injections of hormones to only two to three days.

"Having established fertility clinic networks across the globe, I understand the urgency with which doctors and patients require better solutions," said Gameto's co-founder and Chairman Martin Varsavsky and founder of North America's largest fertility clinic network Inception Prelude. "Fertilo has the potential to transform IVF—making it safer, faster, and more affordable. This funding is a significant step towards that goal."